

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
PACIFICO Yokohama Conference Center	Room 1 Main Hall (1F)		Web Symposium 26 Can Chronomedicine Change Neurology Practice?				LS-30 Eli Lilly Japan K.K.	Web PL-02 Plenary Lecture 02 Speaker: Guy Rouleau Chair: Norihiro Suzuki	Web PL-03 AI Plenary Lecture 03 Speaker: Masasumi Nangaku Chair: Kazutoshi Nishiyama	Web 2026 Special Symposium 02 Role of Neurologists in Common Neurological Diseases							
	Room 2 301 (3F)		Neuroscience Frontier Symposium 01 Competition and Co-Creation in ALS Drug Development		O-23 Motor neuron disease 3		LS-31 Biogen Japan Ltd.				Neuroscience Frontier Symposium 02 Multidisciplinary comprehensive epilepsy research in the world :from basic, AI to clinical domain						
	Room 3 302 (3F)		Web Symposium 27 A New Era in Migraine Management: Multidimensional Approaches		O-24 Headache and Related Neuropathology		LS-32 Alexion Pharma GK				Web Symposium 32 New Trends in the Practice of Functional Neurological Disorders						
	Room 4 303 (3F)				O-25 Dementia 2		LS-33 CSL Behring, K.K.				Symposium 33 Old and New Neuro-Ophthalmology - The Forefront of Neuro-Ophthalmology						
	Room 5 304 (3F)				O-26 Parkinson's disease 3		LS-34 Sumitomo Pharma Co.,Ltd										
	Room 6 311+312 (3F)				O-27 Neuropsychology		LS-35 UCB Japan Co.,Ltd. Medical Affairs										
	Room 7 313+314 (3F)				O-28 Neurorehabilitation, Medical engineering, Medical treatment for incurable diseases		LS-36 GlaxoSmithKline K.K.										
	Room 8 315 (3F)		Symposium 28 INPH (Hakim's disease) and neurodegenerative diseases: coincidental complications, mutually induced, or single disease entity? How to think and treat?		O-29 Motor neuron disease 4		LS-37 Novartis Pharma K.K.				Symposium 34 Clinical Neuropsychology Challenges: The Role of Cognitive Biomarkers						
	Room 9 414+415 (4F)		Symposium 29 Understanding neurological disorders through large-scale genome analysis		O-30 Neuroimmunology 3		LS-38 Eisai Co., Ltd.				Symposium 35 multidisciplinary support for patient with intractable neurological disease						
	Room 10 416+417 (4F)		Web AAN From the AAN President to the members of the JSN		O-31 Parkinson's disease 4		LS-39 Cosmic Corporation Co., Ltd.				Web Neuroscience Frontier Symposium 03 Next generation quantitative assessment of neurological symptoms using digital devices						
	Room 11 418 (4F)		Symposium 30 Career Pathways for Neurologists in Endovascular Therapy		O-32 Cerebrovascular disease 3		LS-40 Fujirebio Inc.				Symposium 36 New risk factors and treatments for progressive multifocal leukoencephalopathy						
	Room 12 419 (4F)		Hot Topics 08 Viruses and Neurodegenerative Diseases: From Novel Pathogenic Insights to Preventive and Therapeutic Strategies		O-33 Neuroimmunology 4		LS-41 T's Pharma Co., Ltd.										
	Room 13 501 (5F)		LM-07 Lecture Marathon 07	LM-08 Lecture Marathon 08	O-34 Dementia 3		LS-42 argenx Japan K.K.				LM-09 Lecture Marathon 09	LM-10 Lecture Marathon 10					
	Room 14 502 (5F)		New Guideline 03 How to Utilize the Latest "2025 Guidelines for the Diagnosis and Treatment of Polymyositis and Dermatomyositis" for Neurologists		O-35 Muscle disease 2		LS-43 CHUGAI PHARMACEUTICAL CO., LTD.				Symposium 37 Deconstructing Neuropsychiatric Symptoms in Parkinson's disease: from phenomenology to pathophysiology						
	Room 15 503 (5F)		Symposium 31 Stroke Oncology, challenges and approach		O-36 Cerebrovascular disease 4		LS-44 Pfizer Japan Inc.				Symposium 38 The actual status of disease modifying anti-tau protein drug						
Poster Session	Hall B (1F)	Poster Preparation / Poster Viewing															
Exhibition		Exhibition															
		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	